Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma® whereas Sun Pharma will promote and distribute the therapy as Gimliand®. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.

ITC has allotted 9,26,900 ordinary shares of Re 1 each under ESOS on 17 November 2025. With this allotment, the paid up equity share capital has increased to Rs 1252,87,64,561/- divided into 1252,87,64,561 Ordinary Shares of Re 1/- each.

WPIL's South African subsidiary has received a contract from METSI KE MATLA JV for complete electro mechanical and instrumentation works for MCWAP2 Project of Trans Caledon Tunnel Authority (South Africa) for a total value of 821m Rand (Rs 426 crore) to be commissioned in 48 months. The said contract does not fall within related party transaction.

Andrew Yule & Company announced that Sharad Kumar, erstwhile General Manager, Cement Corporation of India has assumed the charge of the post of Director (Planning) of the company with effect from today i.e. 17 November 2025 for a period of 5 (five) years.

Precision Electronics has received an order worth Rs 1.12 crore from a government entity in the defense segment for supply of Quadripod/Tripod accessories.

VLS Finance will hold a meeting of the Board of Directors of the Company on 22 November 2025.

Lupin announced that the United States Food and Drug Administration (U.S. FDA) has completed a product specific Pre Approval Inspection at its Unit-1 oral solid dosage manufacturing facility in Nagpur. The inspection was carried out from 10 November to 14 November 2025, and concluded with zero 483 observations.

Nilesh Gupta, Managing Director, Lupin said, “The successful outcome of the U.S. FDA inspection at our Nagpur Unit-1 facility exemplifies our commitment to uphold and maintain the highest standards of quality, compliance, and safety across our facilities. We remain dedicated to improving the lives of our patients globally.”

Stellant Securities (India) announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 10 December 2025.

Transgene Biotek announced that the 35th Annual General Meeting(AGM) of the company will be held on 30 December 2025.

Vimta Labs has allotted 94,369 equity shares under ESOP on 17 November 2025. With this allotment, the paid up equity share capital has increased to Rs 8,92,70,378 consisting of 4,46,35,189 equity shares having a face value of Rs 2 each.